Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 496 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR November is National Family Caregivers Month November 24, 2020 Patritumab Deruxtecan Demonstrates a Manageable Safety Profile and Durable Efficacy in... October 19, 2023 Dear Prime Minister: “Please don’t delay action again, we’re counting on... October 16, 2020 Grandparents of children with cancer: “I would never want to go... September 1, 2020 Load more HOT NEWS EMA Recommends Extension of Indications for Daratumumab FDA Grants Regular Approval to Dostarlimab-gxly for dMMR Endometrial Cancer Significant Intracranial Efficacy and Survival Benefits of Osimertinib in Patients with... Researchers Develop a Potential “Universal” CAR T-Cell Therapy for Blood Cancers
